Biotechnology Biohaven Underscores Depth of Migraine Portfolio with Data from Nurtec® ODT (rimegepant) Long-Term Open Label Study and Phase 3 Zavegepant Trial at 64th Annual Scientific Meeting of the American Headache Society June 9, 2022
Biotechnology BridgeBio Pharma to Present Phase 2b Data and Pivotal Phase 3 Study Design of Encaleret in Autosomal Dominant Hypocalcemia Type 1 (ADH1) at the Endocrine Society (ENDO) 2022 Annual Conference June 9, 2022
Biotechnology Blueprint Medicines Reports Continued Progress Toward Goal of Transforming Treatment of Systemic Mastocytosis June 9, 2022
Biotechnology SHAREHOLDER ALERT: NTRA OSCR AXSM: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines June 8, 2022
Biotechnology AXSM SHAREHOLDER ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM June 8, 2022
Search
Biotechnology
